DIFLORASONE DIACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIFLORASONE DIACETATE (DIFLORASONE DIACETATE).
Diflorasone diacetate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby controlling the biosynthesis of potent mediators of inflammation like prostaglandins and leukotrienes.
| Metabolism | Topical corticosteroids are metabolized primarily in the liver via reduction, oxidation, and conjugation pathways. Specific enzymes for diflorasone diacetate are not well characterized. |
| Excretion | Primarily renal (≤5% unchanged); extensive hepatic metabolism with biliary/fecal elimination of metabolites; total recovery: ~60% in urine (metabolites), ~30% in feces. |
| Half-life | Terminal elimination half-life of approximately 5.7 hours (range 4.4–7.1 h) after topical application; prolonged in hepatic impairment. |
| Protein binding | ~90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Not well characterized for topical route; systemic Vd after IV administration in animal models is approximately 1–2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic bioavailability is low (<1%) when applied to intact skin; may increase to 2–10% on abraded or inflamed skin; occlusive dressings enhance absorption. |
| Onset of Action | Topical: Noticeable relief of pruritus and inflammation within 12–24 hours; maximal effect typically within 1–2 weeks of regular application. |
| Duration of Action | Topical: Therapeutic effect persists for 24 hours after a single application; sustained use recommended for up to 2 weeks for full benefit. |
Apply a thin film to affected skin areas twice daily (every 12 hours). Use the lowest effective strength and duration.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment; systemic absorption is minimal with topical use. |
| Liver impairment | No dosage adjustment required for hepatic impairment; minimal systemic absorption. |
| Pediatric use | Use lowest potency and shortest duration; avoid use in infants under 1 year. For children 1-12 years, apply a thin film once or twice daily, limit to small areas. Safety and efficacy not fully established. |
| Geriatric use | Use with caution due to thinner skin and increased risk of skin atrophy; apply smallest amount for shortest duration necessary. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIFLORASONE DIACETATE (DIFLORASONE DIACETATE).
| Breastfeeding | It is not known whether diflorasone diacetate is excreted in human milk. Systemic absorption is minimal, so amounts in milk are likely low. However, caution is advised, especially if applied to large areas or for prolonged periods. No M/P ratio available. |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used appropriately. Diflorasone diacetate is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects with topical corticosteroids, but there are no adequate human studies. Systemic absorption is minimal with topical application, but risk cannot be excluded. First trimester: theoretical risk; second and third trimesters: low risk with short-term use on limited areas. Avoid prolonged use or application to large areas. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to diflorasone diacetate or any component of the formulation","Untreated bacterial, fungal, viral, or parasitic skin infections"]
| Precautions | ["Systemic absorption may lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.","Pediatric patients may be more susceptible to systemic toxicity due to larger skin surface-to-body weight ratio.","Prolonged use, use on large areas, occlusive dressing, or on broken skin increases systemic absorption.","Local adverse reactions include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria."] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal signs of HPA axis suppression (e.g., weight gain, hyperglycemia, hypertension) if used extensively. Fetal monitoring not routinely required unless high-dose or prolonged use; consider ultrasound for growth assessment with chronic use. |
| Fertility Effects | No known effects on fertility in humans. Animal studies have not reported reproductive impairment. High-dose systemic corticosteroids may affect fertility, but topical application unlikely. |